Mechanism and application of metformin in kidney diseases: An update - 16/04/21
pages | 12 |
Iconographies | 2 |
Vidéos | 0 |
Autres | 0 |
Abstract |
Metformin is an oral antihyperglycemic drug widely used to treat type 2 diabetes mellitus (T2DM), acting via indirect activation of 5′ Adenosine monophosphate-activated Protein Kinase (AMPK). Beyond the anti-diabetic effect, accumulative pieces of evidence have revealed that metformin also everts a beneficial effect in diverse kidney diseases. In various acute kidney diseases (AKI) animal models, metformin protects renal tubular cells from inflammation, apoptosis, reactive oxygen stress (ROS), endoplasmic reticulum (ER) stress, epithelial-mesenchymal transition (EMT) via AMPK activation. In diabetic kidney disease (DKD), metformin also alleviates podocyte loss, mesangial cells apoptosis, and tubular cells senescence through AMPK-mediated signaling pathways. Besides, metformin inhibits cystic fibrosis transmembrane conductance regulator (CFTR)-mediated fluids secretion and the mammalian target of rapamycin (mTOR)-involved cyst formation negatively regulated by AMPK in autosomal dominant polycystic kidney disease (APDKD). Furthermore, metformin also contributes to the alleviation of urolithiasis and renal cell carcinoma (RCC). As the common pathway for chronic kidney disease (CKD) progressing towards end-stage renal disease (ESRD), renal fibrosis is ameliorated by metformin, to a great extent dependent on AMPK activation. However, clinical data are not always consistent with preclinical data, some clinical investigations showed the unmeaningful even detrimental effect of metformin on T2DM patients with kidney diseases. Most importantly, metformin-associated lactic acidosis (MALA) is a vital issue restricting the application of metformin. Thus, we conclude the application of metformin in kidney diseases and uncover the underlying molecular mechanisms in this review.
Le texte complet de cet article est disponible en PDF.Highlights |
• | Beyond the anti-diabetic effect, metformin also everts the pleiotropic effects in diverse renal diseases. |
• | Metformin plays a renoprotective role in various kidney diseases under different etiologic settings. |
• | Metformin should be carefully administered to patients with impaired renal function. |
Abbreviations : T2DM, AMPK, AKI, ROS, ER, EMT, DKD, CFTR, mTOR, ADPKD, RCC, CKD, ESRD, MALA, eGFR, DM, CaOx, ccRCC, STZ, PKD, PAC, EG, FSGS, UUO, IRI, CAM, TGF, MAD, OCT, LK, CREB, CRTC2, PPAR, PGC, PEPCK, G6Pase, GLUT, GLP, GDP, NMP, MACE, TREAT, SHIP2, TRPC6, HPC, RMC, PP2A, NF-κB, ENaC, PKA, ERK, TSC, BMI, OPN, MCP-1, SOD, NSAID, DFS, CSS, mRCC, OS, c-FLIP, GD, RCTs, Nx, ACC, CsA, ERK1/2, ECM, STAT3, LA, MILA, OADs, FDA
Keywords : Metformin, Type 2 diabetes mellitus, Acute kidney injury, Diabetic kidney disease, Autosomal dominant polycystic kidney disease, Metformin-associated lactic acidosis
Plan
Vol 138
Article 111454- juin 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?